| Company Name | AbbVie Biopharmaceuticals GmbH Taiwan Branch |
|---|---|
| Protocol Number | H19-473 |
| Title of Study | Real World Treatment Patterns and Clinical Outcomes in Unfit AML Patients Receiving First Line Systemic Treatment or Best. |
| Primary Objective | To evaluate the overall survival of AML patients unfit for intensive chemotherapy and who received systemic treatment including Low Intensity Chemotherapy (LIC), targeted therapy or Best Supportive Care (BSC) in the real world setting. |
| Number of Sites | 3 |
| Period of Study | From：2019/11/15 to：2020/12/31 |
| Number of Patients | 80人 |
| IRB Approval Date | CMUH: 2019/11/13 KMUH: 2019/10/29 NTUH: 2019/11/11 |
| Publication Plan / Date |
